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Abstract
Background: The purpose of this study was to assess the prevalence, associated factors, and impact on mortality of
primary respiratory disease in a large systemic lupus erythematosus (SLE) retrospective cohort.
Methods: All adult patients in the RELESSER-TRANS (Registry of Systemic Lupus Erythematosus Patients of the
Spanish Society of Rheumatology [SER], cross-sectional phase) registry were retrospectively investigated for the
presence of primary pleuropulmonary manifestations.
Results: In total 3215 patients were included. At least one pleuropulmonary manifestation was present in 31% of
patients. The most common manifestation was pleural disease (21%), followed by lupus pneumonitis (3.6%),
pulmonary thromboembolism (2.9%), primary pulmonary hypertension (2.4%), diffuse interstitial lung disease
(2%), alveolar hemorrhage (0.8%), and shrinking lung syndrome (0.8%).
In the multivariable analysis, the variables associated with the development of pleuropulmonary manifestation
were older age at disease onset (odds ratio (OR) 1.03, 95% confidence interval (CI) 1.02–1.04), higher SLEDAI
(Systemic Lupus Erythematosus Disease Activity Index) scores (OR 1.03, 95% CI 1.00–1.07), the presence of
Raynaud’s phenomenon (OR 1.41, 95% CI 1.09–1.84), secondary antiphospholipid syndrome (OR 2.20, 95% CI
1.63–2.97), and the previous or concomitant occurrence of severe lupus nephritis, (OR 1.48, 95% CI 1.12–1.95)
neuropsychiatric manifestations (OR 1.49, 95% CI 1.11–2.02), non-ischemic cardiac disease (OR 2.91, 95% CI
1.90–4.15), vasculitis (OR 1.81, 95% CI 1.25–2.62), hematological manifestations (OR 1.31, 95% CI 1.00–1.71), and
gastrointestinal manifestations, excluding hepatitis (OR 2.05, 95% CI 1.14–3.66). Anti-RNP positivity had a clear tendency
to significance (OR 1.32, 95% CI 1.00–1.75; P = 0.054).
The development of pleuropulmonary manifestations independently contributes to a diminished survival (hazard ratio
of 3.13). However, not all complications will influence the prognosis in the same way. Whereas the occurrence of
pleural disease or pulmonary thromboembolism has a minimal impact on the survival of these patients, the remaining
manifestations have a major impact on mortality.
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Conclusion: Except for pleural disease, the remaining respiratory manifestations are very uncommon in SLE (<4%).
Pleuropulmonary manifestations independently contributed to a decreased survival in these patients.
Keywords: Systemic lupus erythematosus, Pleuropulmonary involvement
Background
Primary respiratory disease in systemic lupus erythema-
tosus (SLE) seems not uncommon, although its exact
prevalence is still unknown, since it has been reported to
occur in 5% to 90% of the patients [1–6]. This wide
range in prevalence may be explained by the characteris-
tics of the patients studied (early or established disease),
whether only symptomatic patients were included or
systematic screening was done, the methodology used
for diagnosis (clinical manifestations and imaging or aut-
opsy findings), and the different study designs.
All components of the respiratory system may be af-
fected during the course of disease. The spectrum of
pulmonary manifestations caused by SLE includes
pleural disease, upper and lower airway dysfunction, pri-
mary pulmonary hypertension, pulmonary thrombo-
embolism, acute reversible hypoxemia, diffuse interstitial
lung disease, acute lupus pneumonitis, diffuse alveolar
hemorrhage, and shrinking lung syndrome [1–16]. Some
patients may have more than one form of pleuropul-
monary involvement during the course of their disease.
The severity of these respiratory complications is highly
variable and ranges from subclinical to potentially
life-threatening conditions.
In general terms, primary respiratory involvement in
SLE is not as well known as other major organ involve-
ment. As in many other aspects of SLE, there is still no
clear explanation for the appearance of such different re-
spiratory manifestations in patients with an identical
underlying disease. Although some associations have
been described [1–6], the risk factors related to the oc-
currence of these complications are still unknown. It is
likely that there are risk factors associated with the de-
velopment of these complications, some of which may
be modifiable.
The appearance of respiratory complications influences
the prognosis (functional and vital) and the accumulated
damage of the disease, although the extent and grade are
still unknown. As the spectrum of pulmonary manifesta-
tions caused by SLE itself is very broad, not all complica-
tions will influence the prognosis in the same way.
The aim of the present study was to investigate the
prevalence, risk factors, and impact on mortality of pri-
mary respiratory disease in patients from the multicenter
Spanish SLE cohort RELESSER-TRANS (Registry of Sys-
temic Lupus Erythematosus Patients of the Spanish Soci-
ety of Rheumatology [SER], cross-sectional phase).
Methods
Patient selection
This is a historical study in which all adult patients in
the RELESSER-TRANS registry were retrospectively in-
vestigated for the presence of primary pleuropulmonary
manifestations.
The RELESSER-TRANS is a hospital-based registry in-
volving a cross-sectional stage, designed to obtain a bet-
ter understanding of SLE in clinical settings. It includes
data from 3679 SLE patients (American College of
Rheumatology [ACR]-1997 criteria) [17] from 45 Span-
ish hospitals. The methodologic and general characteris-
tics of the RELESSER registry were published previously
[18] (Additional file 1).
Pleuropulmonary manifestations analyzed in this study
included (1) pleural disease, including patients with epi-
sodes of pleurisy according with the SELENA-SLEDAI
(Systemic Lupus Erythematosus Disease Activity Index)
definition [19], or pleural fibrosis according with the
Systemic Lupus International Collaborating Clinics
(SLICC)/ACR-damage index (SDI) [20] or both; (2)
acute lupus pneumonitis or interstitial alveolitis/pneu-
monitis (in accordance with the British Isles Lupus As-
sessment group [BILAG] 2004 definition) [21, 22]; (3)
diffuse interstitial lung disease or pulmonary fibrosis
(SDI definition); (4) pulmonary hemorrhage (BILAG
2004 definition); (5) shrinking lung syndrome (BILAG
2004 definition); (6) primary pulmonary hypertension
(SDI definition); and (7) pulmonary thromboembolism,
including the cases registered with pulmonary infarction
in accordance with the SDI definition. Upper and lower
airway dysfunction and acute reversible hypoxemia were
not included in the study as these two manifestations
were not specifically recorded in the RELESSER data-
base. Respiratory involvement was considered primary
when it was directly related to SLE activity, and infec-
tions, drug toxicity, chronic obstructive pulmonary dis-
ease, occupational exposure, and neoplasia had been
excluded.
The study protocol was approved by the institutional
ethics committee of the Hospital Universitario Doctor
Negrín and subsequently by the local ethics committee of
all participating centers. Informed consent was obtained
from the patients, and their clinical records and informa-
tion were anonymized prior to analysis. Confidential infor-
mation of the patients was protected in accordance with
national norms. This study was conducted in accordance
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with the principles of the Declaration of Helsinki and the
International Conference for Harmonization.
Statistical analysis
Numerical variables were expressed as mean or median
and standard deviation. The categorical variables were
described by absolute frequency and percentage.
Comparisons of numerical variables were obtained by
using a Student t test or a Mann–Whitney U test, ac-
cording to normality adjustments, and of categorical var-
iables by using a chi-squared or Fisher’s exact test as
necessary.
Variables reaching statistical significance in the un-
adjusted analysis were entered in a multivariate model
(Cox proportional hazards regression) to identify risk
factors for the development of pleuropulmonary compli-
cations. The selection of variables in the model was
made while taking into account its individual associ-
ation, the multicollinearity between different variables,
and its importance as a confounding factor that justified
its inclusion as an adjustment variable.
Survival analysis (Kaplan–Meier) was conducted to
assess whether the development of respiratory disease
was associated with lower survival in patients with
lupus and to explore the influence on the prognosis
of each analyzed respiratory manifestation. Subse-
quent comparisons between survival curves were
made by using a log-rank test.
To determine the independent contribution of the
presence of pleuropulmonary manifestations to mortal-
ity, a multivariable Cox regression analysis was carried
out. The following variables were considered candidates
for inclusion: age, gender, infections, nephritis, cardiac
involvement, cardiovascular and cerebrovascular events,
and SLEDAI and SLICC scores. Pleuropulmonary mani-
festations were considered a time-dependent variable.
Statistical significance was assumed as a P value of less
than 0.05.
Results
Demographic data
Of the 3679 patients included in the RELESSER-TRANS,
3215 patients were finally included in this study (after
excluding those in whom respiratory manifestations had
not been collected and cases in which there were doubts
as to whether the pulmonary condition could be directly
related to SLE activity). Of these, 91% were female and
9% were male; mean age at SLE diagnosis (± standard
deviation) was 37 ± 13 years (range 19–86), and median
disease duration was 118 ± 98months (range 61–196).
The main baseline demographic and clinical characteris-
tics of the SLE study cohort are shown in Table 1.
Pleuropulmonary manifestations
At least one pleuropulmonary manifestation was present
in 996 patients (31%): 920 patients developed one mani-
festation, 56 two, 19 three, and 1 four. The most com-
mon manifestation was pleural disease, occurring in 680
(21%) of patients, followed by lupus pneumonitis in 118
(3.6%), pulmonary thromboembolism in 95 (2.9%), pri-
mary pulmonary hypertension in 79 (2.4%), diffuse inter-
stitial lung disease in 65 (2%), alveolar hemorrhage in 28
(0.8%), and shrinking lung syndrome in 28 (0.8%).
Respiratory manifestations may complicate SLE at any
time during its course, although they usually occur later in
the course of the disease. The mean time from diagnosis
of SLE to the first appearance of respiratory manifesta-
tions was 5.8 (standard deviation 8.3) years; the mean dis-
ease duration for each manifestation was pleurisy 7.6 years
(8.6), acute lupus pneumonitis 5.4 years (7.6), diffuse inter-
stitial lung disease/pulmonary fibrosis 7.7 years (10.5),
alveolar hemorrhage 5.2 years (7.5), shrinking lung syn-
drome 6 years (6.8), primary pulmonary hypertension 9.2
years (9.2), and pulmonary thromboembolism 3.9 years
(7.9). In 4% of the cases, respiratory manifestations were
the presenting symptoms of SLE (including cases of pleur-
isy, shrinking lung syndrome, and diffuse alveolar
hemorrhage). Twenty-two percent of patients with acute
lupus pneumonitis (26 out of 118) and 21% of patients
with alveolar hemorrhage (6 out of 28) who survived fi-
nally developed pulmonary fibrosis.
Other previous and concomitant clinical manifestations of
SLE
As shown in Table 1, the majority of patients who devel-
oped pleuropulmonary manifestations also had previous
or concomitant involvement of other major organs. The
most common clinical features of lupus were arthritis and
dermatologic involvement and, less commonly, pericardi-
tis. Nephritis was documented in 39% of the patients,
non-ischemic cardiac disease in 16%, neuropsychiatric in-
volvement in 11%, vasculitis in 8%, and gastrointestinal in-
volvement in 5%.
In regard to their autoantibody profiles, 72% of pa-
tients tested positive for anti-double stranded DNA anti-
bodies and 76.5% had hypocomplementemia at some
time during the course of the disease. Anti-Sm anti-
bodies were positive in 21%, anti-RNP in 25%, and
anti-Ro in 40% of the patients in whom this information
was available. The frequency of antiphospholipid anti-
body (aPL) positivity was also remarkable: anticardiolipin
antibodies (IgM or IgG) 20%, anti-beta-2 glycoprotein 1
(IgM or IgG) 13.5%, and lupus anticoagulant 23%.
Patients with respiratory complications had higher
S-SLEDAI scores (3.65 ± 2.25 versus 2.72 ± 2.43; P
<0.001) at the last visit (when enrollment in the registry
occurred). As expected, the mean SDI scores were also
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significantly higher in this group than in patients with
no pleuropulmonary involvement (2.39 ± 3.34 versus
0.90 ± 1.40; P <0.001). Of interest, when lung manifesta-
tions were excluded from the SDI, the differences
remained (1.57 ± 2.13 versus 0.62 ± 1.22; P <0.01). From
these data it can be inferred that the development of re-
spiratory complications has an important weighting in
the accumulated damage of the disease.
Factors associated with the development of
pleuropulmonary complications
The results of the univariate and multivariate analysis are
shown in Table 2. In the multivariate analysis, the variables
independently associated with the development of pleuro-
pulmonary manifestation were older age at disease onset
(odds ratio (OR) 1.03, 95% confidence interval (CI) 1.02–
1.04), higher SLEDAI scores (OR 1.03, 95% CI 1.00–1.07),
the presence of Raynaud’s phenomenon (OR 1.41, 95% CI
1.09–1.84), secondary antiphospholipid syndrome (OR
2.20, 95% CI 1.63–2.97), and the previous or concomitant
occurrence of severe lupus nephritis (including classes III,
IV, V, and mixed III/IV + V) (OR 1.48, 95% CI 1.12–1.95),
neuropsychiatric manifestations (OR 1.49, 95% CI 1.11–
Table 1 Baseline demographic and clinical characteristics of the
systemic lupus erythematosus study cohort
Demographic characteristics
Number of patients 3215
Women/Men 2925 (91%)/290 (9%)
Age at SLE diagnosis, mean
± SD
37 ± 13 (range, 19–86 years)
Age at the time of RELESSER-
TRANS inclusion, mean ± SD
48 ± 14 (range, 19–94 years)
Ethnic groups Caucasians: 93%/Hispanics: 5.4%/
African-Americans: 0.2%/Asians:
0.6%/Others: 0.8%
Tobacco Never: 58%/Before: 25%/At the time
of RELESSER-TRANS inclusion: 17%
Clinical manifestations
Constitutional symptoms Fever 3.6%/Weight loss 9.5%
Cutaneous 64%
Arthritis 78%
Raynaud’s phenomenon 35%
Vasculitis 10%
Nephritis 31%
Gastrointestinal involvement 3%
Hepatitis 2.8%
Pericarditis 15%
Non-ischemic cardiac disease 4.5%
Neuropsychiatric manifestations 6.5%
Hematologic 79%
Lymphadenopathy/
Splenomegaly
9.7%/2.9%
Secondary antiphospholipid
syndrome
17%
SLEDAI score, mean ± SD 2.62 ± 3.69
SDI score, mean ± SD 1.15 ± 1.68
Immunological laboratory*
Anti-dsDNA antibody positivity
(available data in all patients)
72%
Hypocomplementemia
(available data in all patients)
76.5%
Anti-Sm antibody positivity
(available in 3048 patients)
21%
Anti-Ro antibody positivity
(available in 3109 patients)
40%
Anti-La antibody positivity
(available in 3108 patients)
19%
Anti-RNP antibody positivity
(available in 3095 patients)
25%
Anticardiolipin antibody
positivity [IgM or IgG]
(available in 2952 patients)
20%
Anti-beta 2 glycoprotein 1
[IgM or IgG] (available in
1918 patients)
13.5%
Table 1 Baseline demographic and clinical characteristics of the
systemic lupus erythematosus study cohort (Continued)
Lupus anticoagulant
(available in 2312 patients)
23%
Treatments**
Corticosteroids 88%
<10mg/daily of prednisone
or equivalent
46.5%
10–30mg/daily 32%
>30–60 mg/daily 21.5%
Antimalarials 83.5%
Methotrexate 17%
Azathioprine 31%
Cyclophosphamide 20%
Mycophenolate 16%
Intravenous immunoglobulins 4%
Plasmapheresis 1.5%
Rituximab 6%
Antiplatelet therapy 36%
Anticoagulants 14%
Abbreviations: RELESSER-TRANS Registry of Systemic Lupus Erythematosus
Patients of the Spanish Society of Rheumatology [SER], cross-sectional phase,
SD standard deviation, SDI Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index, SLE systemic lupus
erythematosus, SLEDAI Systemic Lupus Erythematosus Disease Activity Index
*Because this is a retrospective (historical) study, not all analyzed variables
were recorded in all included cases. Thus, the percentage for each variable
was calculated for only those patients in which the data were documented
** Treatments recorded in the RELESSER-TRANS registry as “any use” or “use at
last visit” (corresponding to the last visit before enrollment) or both
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2.02), non-ischemic cardiac disease (OR 2.91, 95% CI 1.90–
4.15), vasculitis (OR 1.81, 95% CI 1.25–2.62), hematological
manifestations (OR 1.31, 95% CI 1.00–1.71), and gastro-
intestinal manifestations, excluding hepatitis (OR 2.05, 95%
CI 1.14–3.66). Anti-RNP positivity had a clear tendency to
significance (OR 1.32, 95% CI 1.00–1.75; P = 0.054).
Mortality
Sixty-one patients with pleuropulmonary manifestations
(1.89%) died over the follow-up period. SLE was the
commonest cause of death, occurring in 0.9% of patients
(28 out of 3215), followed by infection in 0.5% (17 out of
3215), cardiovascular and cerebrovascular disease in
0.3% (11 out of 3215), and cancer in 0.1% (5 out of
3215). Although the mortality rate was low, the develop-
ment of respiratory disease was associated with lower
survival (survival rates 95.6% versus 82.2%, P = 0.030;
Fig. 1). After adjustment for known confounders in the
multivariable Cox regression model (Table 3), pleuropul-
monary manifestations remained a risk factor for
Table 2 Variables associated with the development of pleuropulmonary manifestations
Without pleuropulmonary
involvement (N = 2219)
With pleuropulmonary
involvement (N = 996)
Univariate
analyses
Multivariate analyses
P value Odds ratio (95% CI) P value
Gender, female (%) 91.5% (2030) 88.3% (880) 0.053 0.86 (0.57–1.29) 0.450
Age at SLE onset, mean ± SD 37 ± 11.6 39.1 ± 13 <0.001 1.03 (1.02–1.04) 0.001
Tobacco (before or at the time of RELESSER-TRANS
inclusion)
41.4% (919) 45.2% (450) 0.015 1.13 (0.88–1.45) 0.350
Clinical manifestations
Arthritis 77.3% (1717) 80% (797) 0.257 1.35 (0.99–1.85) 0.069
Cutaneous 64.9% (1440) 62.6% (623) 0.568
Raynaud’s phenomenon 32.6% (723) 41.9% (417) <0.001 1.41 (1.09–1.84) 0.015
Vasculitis 7.2% (160) 17.6% (175) <0.001 1.81 (1.25–2.62) 0.002
Nephritis 26.8% (595) 39% (389) 0.043 1.30 (0.98–1.73) 0.068
Severe lupus nephritis (only including classes III, IV,
V, and mixed III/IV + V)
20.2% (450) 26.7% (266) <0.001 1.48 (1.12–1.95) 0.002
Non-ischemic cardiac disease, excluding pericarditis 2.3% (52) 9.3% (93) <0.001 2.91 (1.90–4.15) 0.001
Gastrointestinal involvement, except hepatitis 2.2% (49) 5.3% (53) 0.001 2.05 (1.14–3.66) 0.016
Hepatitis 2.3% (51) 3.9% (39) 0.078 0.75 (0.35–1.60) 0.453
Hematologic abnormalities 76.7% (1701) 84.3% (840) 0.001 1.31 (1.00–1.71) 0.048
Neuropsychiatric manifestations 4.4% (98) (112) <0.001 1.49 (1.11–2.02) 0.009
Secondary antiphospholipid syndrome 12% (266) 27.9% (278) <0.001 2.20 (1.63–2.97) 0.000
SLEDAI score, mean ± SD 2.72 ± 2.43 3.65 ± 2.25 <0.001 1.03 (1.00–1.07) 0.021
SDI score, mean ± SD 0.90 ± 1.40 2.39 ± 3.34 <0.001
Immunological laboratory*
Anti-dsDNA antibody positivity 71.3% (1978/2772) 76.7% (277/361) 0.072
Hypocomplementemia 76.2% (2123/2785) 77.9% (278/357) 0.085
Anti-Sm antibody positivity 20.2% (545/2701) 23.6% (82/347) 0.134
Anti-Ro antibody positivity 40.8% (1126/2760) 36.1% (126/349) 0.092
Anti-La antibody positivity 19.7% (543/2756) 16.5% (58/352) 0.149
Anti-RNP antibody positivity 23.9% (657/2744) 30.5% (107/351) 0.007 1.32 (1.00–1.75) 0.054
Anticardiolipin antibody positivity (IgM or IgG) 19.9% (520/2616) 21.7% (73/336) 0.426
Anti-beta 2 glycoprotein 1 (IgM or IgG) 13.3% (226/1697) 14.9% (33/221) 0.509
Lupus anticoagulant 22.2% (455/2049) 30.1% (82/272) 0.004
Results are presented as percentage (and number of cases) or mean ± standard deviation
Abbreviations: CI confidence interval, RELESSER-TRANS Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology [SER], cross-
sectional phase, SD standard deviation, SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, SLE systemic
lupus erythematosus, SLEDAI Systemic Lupus Erythematosus Disease Activity Index
* Because this is a retrospective (historical) study, not all analyzed variables were available in all included cases. Thus, the percentage for each variable was
calculated for only those patients in which the data were documented
Statistical significance was assumed as a p value of less than 0.05 (bold data)
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diminished survival (hazard ratio 3.13, 95% CI 1.56–
6.28, P = 0.001).
Since not all complications influenced the prognosis in
the same way, survival analysis analyzing the presence of
each individual respiratory manifestation was conducted:
(1) considering only the presence of pleural disease: sur-
vival rates of 82.9% versus 95.6% (no pleuritis) (P =
0.101); (2) considering only the presence of pulmonary
thromboembolism: survival rates of 88.7% versus 95.6%
(P = 0.253); (3) considering only the presence of shrink-
ing lung syndrome: survival rates of 80.9% versus 95.6%
(P = 0.567); (4) considering only the presence of diffuse
interstitial lung disease: survival rates of 79.7% versus
95.6% (P <0.01); (5) considering only the presence of
pneumonitis: survival rates of 78.6% versus 95.6% (P
<0.01); (6) considering only the presence of primary pul-
monary hypertension: survival rates of 76.1% versus
95.6% (P <0.01); and (7) considering only the presence
of alveolar hemorrhage: survival rates of 55.6% versus
95.6% (P <0.001).
Discussion
The heterogeneity of disease course and outcome in
SLE, coupled with its low prevalence, make it difficult
for physicians to acquire sufficient clinical experience in
the absence of standardization and collaborative efforts.
Therefore, much of the clinical research on SLE has
been based primarily on registries and on their derived
cohorts, which have been an important source of new
knowledge about the disease. Studies derived from regis-
tries usually have a large number of patients from
non-experimental clinical settings and allow a more ex-
tensive follow-up than can be accomplished in clinical
trials, providing more reliable answers to specific
0.
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analysis time
Kaplan-Meier survival estimates
Respiratory diseaseNo respiratory disease
P = 0.030
Survival (%)
(yrs)
Fig. 1 Survival analysis (Kaplan–Meier) comparing patients with and without primary respiratory disease
Table 3 Cox regression of predictors of mortality in lupus patients from the RELESSER-TRANS cohort
Hazard ratio 95% confidence interval P value
Pleuropulmonary manifestations 3.13 1.56–6.28 0.001
Age 0.99 0.96–1.01 0.293
Gender 0.89 0.31–2.52 0.825
Infections 0.79 0.39–1.59 0.506
Nephritis 0.74 0.23–2.39 0.612
Cardiac disease 1.01 0.42–2.42 0.978
Cardiovascular events 1.57 0.32–7.66 0.577
SLEDAI score 1.08 1.00–1.16 0.052
SLICC score 1.79 0.69–0.92 0.002
Abbreviations: RELESSER-TRANS Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology [SER], cross-sectional phase, SLEDAI
Systemic Lupus Erythematosus Disease Activity Index, SLICC Systemic Lupus International Collaborating Clinics
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questions. In this case, this applied to primary respira-
tory involvement in SLE, which is not as well known as
other major organ involvement.
According to the data from our registry, the overall
prevalence of symptomatic pleuropulmonary manifesta-
tions in this SLE population was 31%, and pleural in-
volvement was the most frequent complication. This
prevalence is higher than that reported in the Eurolupus
project (7%) [23] and is similar to that reported in the
Latin American SLE cohort (Grupo Latinoamericano de
Estudio del Lupus, or GLADEL), which recently exam-
ined this specific clinical aspect (28%) [2]. Prevalence
rates from these three multicenter registries demonstrate
that primary respiratory disease occurs in about 25–30%
of patients with lupus during the course of the disease.
Apart from pleural disease that occurs in 21% of pa-
tients, the other respiratory manifestations are uncom-
mon, occurring in less than 4% of cases. Of the lung
parenchymal manifestations, the most commonly ob-
served was pneumonitis (3.6%). This is consistent with
observations from other registries in which it was also
the most frequent parenchymal complication; the re-
ported prevalence was between 2.4% and 4% [2, 24].
Pleuropulmonary involvement may complicate SLE
at any time during its course, although it is more fre-
quent later in the course of the disease (mean disease
duration of about 6 years). Data from the LUMINA
(Lupus in minorities: nature versus nurture) multieth-
nic cohort also documented the development of pul-
monary damage (as defined by SDI) after a mean
disease duration of 5.3 years [13]. More rarely (4% of
cases in our study), respiratory complications may be
the presenting manifestation of SLE. This has been
described with pleurisy, shrinking lung syndrome, dif-
fuse alveolar hemorrhage, acute lupus pneumonitis,
and pulmonary thromboembolism [14, 16, 24, 25].
In most patients, pleuropulmonary involvement occurs
in the setting of previous or concomitant involvement of
other major organs. Apart from the frequent presence of
systemic, cutaneous, and musculoskeletal symptoms, a
considerable proportion of these patients have or have
had nephritis (39% in our series and 40% of cases in the
GLADEL registry), neuropsychiatric involvement (11%
and 14%, respectively), and non-ischemic heart disease
(16% and 14%, respectively) [2]. According to our study,
the history of pericarditis, vasculitis, and gastrointestinal
involvement is also frequent in this group of patients.
From these data it can be inferred that the development
of respiratory complications occurs in patients with a se-
vere disease, with higher mean SDI scores even when
lung manifestations are excluded.
In fact, patients with active disease (defined by higher
SLEDAI scores) and the previous or concomitant presence
of severe lupus nephritis, neuropsychiatric manifestations,
non-ischemic cardiac disease, hematological manifesta-
tions, and gastrointestinal involvement, those with Ray-
naud’s phenomenon, and those who had secondary
antiphospholipid syndrome are predisposed to the occur-
rence of pleuropulmonary manifestations. Another pre-
dictive factor is older age. It cannot be ruled out that, in
addition to antiphospholipid antibodies, anti-RNP anti-
bodies could be related to the development of pleuropul-
monary manifestations; in our study, anti-RNP positivity
had a clear tendency to significance (OR 1.32, 95% CI
1.00–1.75; P = 0.054) and previous investigations support
this relationship.
Some of these associated factors are coincident with
those reported in other studies. In the LUMINA registry,
older age and the presence of anti-RNP antibodies were
associated with a shorter time to the development of per-
manent lung disease [13]. In the GLADEL registry, older
age and the presence of systemic symptoms, non-ischemic
heart disease, and nephritis were also associated with the
occurrence of pleuropulmonary manifestations [2].
A strong association between aPL and pulmonary
thromboembolism has been well documented in SLE
[26]. In addition, new evidence suggests that aPL in pa-
tients with SLE increases the risk of primary pulmonary
hypertension [27]. Hypotheses regarding the impact of
aPL on pulmonary hypertension include large vessel and
microvascular thrombosis and endothelial remodeling
[27]. Diffuse alveolar hemorrhage may rarely occur in
antiphospholipid syndrome and may be the initial mani-
festation [28]. The proposed mechanism in SLE is a nec-
rotizing microangiitis related to immune complex
deposition and induction of apoptosis, involving alveolar
capillaries [29]. In antiphospholipid syndrome, histo-
pathological studies show alveolar hemorrhage and
microvascular thrombosis with or without pulmonary
capillaritis [30]. The fact that SLE and antiphospholipid
syndrome have a wide spectrum of pulmonary manifes-
tations, some of which may be very similar, has raised
the question of common pathological processes [31]. Fi-
nally, a greater frequency of Raynaud’s phenomenon in
patients with SLE and primary pulmonary hypertension
has been documented (60% versus 20%–30% in those
without this complication) [32]. Shen et al. have shown
that patients with pulmonary hypertensive SLE had
higher serum endothelin levels, their lupus was more ac-
tive, and they presented with Raynaud’s phenomenon,
suggesting that pulmonary arterial vasospasm could play
an important role in the pathogenesis of this complica-
tion [33]. Finally, Wang et al., in a recently published
meta-analysis, identified the anti-RNP antibody and
anti-Sm antibody as risk factors for SLE-associated pul-
monary arterial hypertension with pooled ORs of 3.68
(95% CI 2.04–6.63, P <0.0001) and 1.71 (95% CI 1.06–
2.76, P = 0.03), respectively [34]. Seropositivity for
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anti-RNP has also been described as a risk factor for the
development of shrinking lung syndrome but this associ-
ation has not been confirmed in all of the studies [16,
35, 36]. Previous investigations have documented a rela-
tionship between anti-Ro, anti-La, and anti-Sm anti-
bodies with some pulmonary manifestations, but we
could not corroborate these associations [2, 37–39].
Primary respiratory disease is an important cause of
morbidity and mortality in SLE. In a previous study
from our group, pleuropulmonary manifestations
represented 3.7% of the total accumulated damage of
the disease in the patients included in the RELESSER-
TRANS as defined by the SDI [40]. As stated in the
LUMINA cohort, cumulative rates of pulmonary dam-
age at 5 and 10 years are 7.6% and 11.6%, respectively
[13]. Another important finding is that 21%–22% of
our patients with acute lupus pneumonitis or alveolar
hemorrhage who survived finally developed pulmon-
ary fibrosis.
Consistent with previous reports, our study corrobo-
rates the fact that pleuropulmonary manifestations inde-
pendently contribute to a diminished survival [2, 41, 42].
However, not all complications will influence the progno-
sis in the same way. Whereas the occurrence of pleural
disease or pulmonary thromboembolism has a minimal
impact on the survival of these patients, the remaining
manifestations have a major impact on mortality (in order
of least to most important: shrinking lung syndrome, dif-
fuse interstitial lung disease, pneumonitis, primary pul-
monary hypertension, and alveolar hemorrhage).
This is a retrospective (historical) study carved into
an existing cohort and has several limitations. First,
the main limitation is that the baseline variables were
collected many years into the course of the disease
rather than at onset. Second, owing to the multipur-
pose nature of the RELESSER-TRANS registry, which
was never specifically designed to study primary re-
spiratory disease in SLE, pleuropulmonary manifesta-
tions were not systematically evaluated, and only the
symptomatic cases were collected. This could lead to
an underestimation of the frequency of some of these
manifestations. Third, not all autoantibodies were
available in all patients, and had not been obtained at
a central laboratory or at the time pleuropulmonary
manifestations occurred. Fourth, we could not exclude
random associations due to the large number of vari-
ables analyzed. However, we have tried to minimize
this risk by using multivariate analysis. Fifth, the main
objectives of this registry did not include analysis of
the specific effects of therapies on individual manifes-
tations. For this reason, in the multivariable Cox re-
gression model of mortality, we have not included
medications known to be either protective (antimalar-
ials) or deleterious (steroids).
Conclusions
Except for pleural disease, the remaining respiratory
manifestations are very uncommon in patients with SLE,
occurring in less than 4% of cases. Of the lung parenchy-
mal manifestations, the most commonly observed was
pneumonitis (3.6%).
They occur later in the course of the disease, mainly
in patients with active and severe lupus (with previous
or concomitant major organ involvement other than
lung), and seem to be associated with older age, the
presence of Raynaud’s phenomenon, and the positivity
of antiphospholipid antibodies. Pleuropulmonary mani-
festations contribute independently to a significantly
decreased survival. However, not all complications will
influence the prognosis in the same way. Whereas the
occurrence of pleural disease or pulmonary thrombo-
embolism has a minimal impact on the survival of these
patients, the remaining manifestations have a major im-
pact on mortality.
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